| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group.
|
Gastroenterology
|
2000
|
2.65
|
|
2
|
Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses.
|
Eur J Cancer
|
1991
|
1.44
|
|
3
|
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
|
Br J Cancer
|
2007
|
1.33
|
|
4
|
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer.
|
Ann Oncol
|
2009
|
1.12
|
|
5
|
Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB.
|
J Biol Chem
|
1996
|
1.11
|
|
6
|
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
|
J Clin Oncol
|
2001
|
1.09
|
|
7
|
Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma.
|
Gynecol Oncol
|
1989
|
1.03
|
|
8
|
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
|
Ann Oncol
|
2008
|
1.02
|
|
9
|
Monoclonal rat antibodies directed against Toxoplasma gondii suitable for studying tachyzoite-bradyzoite interconversion in vivo.
|
Clin Diagn Lab Immunol
|
1995
|
1.00
|
|
10
|
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
|
Eur J Cancer
|
2006
|
0.96
|
|
11
|
Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation.
|
Int J Cancer
|
1995
|
0.96
|
|
12
|
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
|
Ann Oncol
|
2011
|
0.95
|
|
13
|
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
|
Leukemia
|
2004
|
0.95
|
|
14
|
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
|
Int J Clin Pharmacol Ther
|
2005
|
0.94
|
|
15
|
Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy.
|
Ann Surg
|
1985
|
0.94
|
|
16
|
Prognostic significance of liver metastases as first site of generalisation in patients with breast cancer--a retrospective analysis.
|
Acta Med Austriaca
|
2001
|
0.93
|
|
17
|
Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.
|
Int J Cancer
|
1995
|
0.91
|
|
18
|
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.
|
Br J Cancer
|
2012
|
0.91
|
|
19
|
Docetaxel extravasation.
|
Support Care Cancer
|
2001
|
0.91
|
|
20
|
Phase II study of E7070 in patients with metastatic melanoma.
|
Ann Oncol
|
2005
|
0.90
|
|
21
|
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
|
Ann Oncol
|
2003
|
0.89
|
|
22
|
[Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
|
Geburtshilfe Frauenheilkd
|
1985
|
0.88
|
|
23
|
The clinical course of lung metastases from breast cancer.
|
Klin Wochenschr
|
1988
|
0.86
|
|
24
|
Regulation of developmental differentiation in the protozoan parasite Toxoplasma gondii.
|
J Eukaryot Microbiol
|
1996
|
0.86
|
|
25
|
The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells.
|
J Cell Sci
|
1991
|
0.86
|
|
26
|
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
|
J Cancer Res Clin Oncol
|
1988
|
0.86
|
|
27
|
Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells.
|
Carcinogenesis
|
1995
|
0.84
|
|
28
|
Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells.
|
J Cell Sci
|
1992
|
0.84
|
|
29
|
Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells.
|
Br J Cancer
|
1992
|
0.83
|
|
30
|
Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene.
|
Br J Cancer
|
1995
|
0.83
|
|
31
|
Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study.
|
Cancer Chemother Pharmacol
|
1996
|
0.83
|
|
32
|
Phase II study of amonafide in advanced breast cancer.
|
Breast Cancer Res Treat
|
1991
|
0.83
|
|
33
|
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
|
Ann Oncol
|
2002
|
0.83
|
|
34
|
The value of second-look operation in patients with advanced epithelial ovarian carcinoma.
|
Arch Gynecol Obstet
|
1989
|
0.83
|
|
35
|
The human tumour cloning assay in the management of breast cancer patients.
|
Br J Cancer
|
1985
|
0.82
|
|
36
|
Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription.
|
Br J Cancer
|
1993
|
0.82
|
|
37
|
Carcinoembryonic antigen (CEA) plasma level determination in the management of gastric cancer patients.
|
Cancer Detect Prev
|
1985
|
0.82
|
|
38
|
Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
|
Klin Wochenschr
|
1989
|
0.81
|
|
39
|
The differential effects of N,N-dimethylformamide and transforming growth factor-beta 1 on a human ovarian cancer cell line (HOC-7).
|
J Cell Physiol
|
1992
|
0.81
|
|
40
|
Separation of clonogenic and differentiated cell phenotypes of ovarian cancer cells (HOC-7) by discontinuous density gradient centrifugation.
|
Cancer Lett
|
1991
|
0.81
|
|
41
|
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
|
Eur J Cancer
|
2004
|
0.80
|
|
42
|
Different propensity for spontaneous differentiation of cell clones isolated from the human ovarian surface epithelial cell line HOC-7.
|
Differentiation
|
1993
|
0.80
|
|
43
|
Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells.
|
Cancer Lett
|
1997
|
0.79
|
|
44
|
Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.
|
Cancer Chemother Pharmacol
|
1995
|
0.79
|
|
45
|
Amonafide as first-line chemotherapy for metastatic breast cancer.
|
Eur J Cancer
|
1994
|
0.79
|
|
46
|
[Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
|
Geburtshilfe Frauenheilkd
|
1985
|
0.79
|
|
47
|
Modulation of the immunophenotype of ovarian cancer cells by N,N-dimethylformamide and transforming growth factor-beta 1.
|
J Cell Physiol
|
1993
|
0.78
|
|
48
|
European School of Oncology. First Euro-American Forum on Lung Cancer Treatment.
|
Eur J Cancer
|
1994
|
0.78
|
|
49
|
Regulation of interleukin-8 gene expression by all-trans retinoic acid.
|
Biochem Biophys Res Commun
|
1995
|
0.78
|
|
50
|
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.
|
Eur J Cancer
|
2002
|
0.78
|
|
51
|
Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells.
|
Br J Cancer
|
1996
|
0.77
|
|
52
|
Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.
|
J Cancer Res Clin Oncol
|
1997
|
0.77
|
|
53
|
[Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II].
|
Geburtshilfe Frauenheilkd
|
1987
|
0.77
|
|
54
|
Long-term remission in a patient with erythroleukemia following interferon-alpha treatment.
|
J Biol Response Mod
|
1989
|
0.76
|
|
55
|
[Abdominal computerized tomography in the after-care of ovarian cancers].
|
Digitale Bilddiagn
|
1986
|
0.76
|
|
56
|
Instability of the anticancer agent etoposide under in vitro culture conditions.
|
Cancer Chemother Pharmacol
|
1991
|
0.76
|
|
57
|
Chemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancer.
|
Oncol Lett
|
2010
|
0.75
|
|
58
|
Crossed immuno-affinity electrophoresis--a method for analysing the interactions of factor VIII-related antigen with vessel wall proteins.
|
Thromb Res
|
1982
|
0.75
|
|
59
|
[The course of the urea cycle in the liver of the chicken (author's transl)].
|
Zentralbl Veterinarmed A
|
1974
|
0.75
|
|
60
|
Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.
|
Cancer Chemother Pharmacol
|
1995
|
0.75
|
|
61
|
The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.
|
Cancer Chemother Pharmacol
|
1990
|
0.75
|
|
62
|
Standard Operating Procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research--EWIV. Preface.
|
Onkologie
|
2003
|
0.75
|
|
63
|
Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure.
|
Br J Surg
|
1985
|
0.75
|
|
64
|
Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration.
|
Chemotherapy
|
1987
|
0.75
|
|
65
|
Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125.
|
Cancer Detect Prev
|
1986
|
0.75
|
|
66
|
Possible adverse effect of failed adjuvant chemotherapy on the prognosis of women receiving consecutive chemotherapy for recurrent breast cancer.
|
J Cancer Res Clin Oncol
|
1987
|
0.75
|
|
67
|
[Immunoassay using the hemoglobin pseudoperoxidase activity as indicator].
|
Z Med Lab Diagn
|
1982
|
0.75
|
|
68
|
[Monitoring of cardiac function during doxorubicin therapy in metastasized breast cancer. Measuring systolic time interval].
|
Dtsch Med Wochenschr
|
1983
|
0.75
|
|
69
|
[Plasmapheresis in extra-intestinal manifestations of Crohn's disease].
|
Wien Klin Wochenschr
|
1984
|
0.75
|
|
70
|
[Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
|
Wien Klin Wochenschr
|
1983
|
0.75
|
|
71
|
[Hepatic tumors].
|
Acta Med Austriaca
|
1983
|
0.75
|
|
72
|
[In vitro chemosensitivity testing with the human tumor stem cell assay (HTSCA) in breast cancer].
|
Wien Klin Wochenschr
|
1984
|
0.75
|
|
73
|
Interferon-alpha induces complete remission in angioimmunoblastic lymphadenopathy (AILD): late development of aplastic anaemia with cytokine abnormalities.
|
Br J Haematol
|
1991
|
0.75
|
|
74
|
[Goserelin--a new form of hormone therapy in ovarian cancer].
|
Gynakol Rundsch
|
1990
|
0.75
|
|
75
|
[Carboplatin, VP-16 in epithelial ovarian cancer--initial experiences].
|
Gynakol Rundsch
|
1988
|
0.75
|
|
76
|
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
|
Wien Klin Wochenschr
|
1991
|
0.75
|
|
77
|
[Adjuvant chemotherapy in patients with radical resection of stomach cancer: 5-year results of a prospective randomized study].
|
Wien Klin Wochenschr
|
1986
|
0.75
|
|
78
|
Blood brain barrier modification and chemotherapy. Interventional neuroradiology in the treatment of malignant gliomas.
|
Acta Radiol Suppl
|
1986
|
0.75
|
|
79
|
[High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study].
|
Gynakol Geburtshilfliche Rundsch
|
1993
|
0.75
|
|
80
|
Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austria.
|
Arch Virol Suppl
|
1992
|
0.75
|
|
81
|
Assessment of the human tumor cloning assay for urologic malignancies with special emphasis on bladder cancer.
|
Oncology
|
1986
|
0.75
|
|
82
|
[Development of an enzyme immunoassay for determination of factor VIII antigens].
|
Acta Biol Med Ger
|
1982
|
0.75
|
|
83
|
Permanent cure of hydroa vacciniforme after chemotherapy for Hodgkin's disease.
|
Br J Dermatol
|
1988
|
0.75
|
|
84
|
Phase II trial of recombinant interferon alpha-2C in metastatic renal cell carcinoma.
|
J Biol Regul Homeost Agents
|
1988
|
0.75
|
|
85
|
[A model of the blood circulation system with extensive pulsing simulation as basis of monitoring artificial heart].
|
Med Tekh
|
1997
|
0.75
|
|
86
|
Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity?
|
Ann Oncol
|
1994
|
0.75
|
|
87
|
The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial.
|
Recent Results Cancer Res
|
1988
|
0.75
|
|
88
|
[Interferon alpha 2C in the treatment of 2 patients with AIDS-associated Kaposi sarcoma].
|
Wien Klin Wochenschr
|
1987
|
0.75
|
|
89
|
[Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
|
Wien Klin Wochenschr
|
1987
|
0.75
|
|
90
|
[Determination of enzymes of the urea cycle, glutaminase and asparaginase in cattle and pigs].
|
Zentralbl Veterinarmed A
|
1974
|
0.75
|
|
91
|
Report on the XV Congress of the European Society for Medical Oncology (ESMO) Copenhagen, December 2-5, 1990.
|
Wien Klin Wochenschr
|
1991
|
0.75
|
|
92
|
[Mitoxantrone in the primary treatment of metastasizing breast cancer].
|
Wien Klin Wochenschr
|
1984
|
0.75
|
|
93
|
[Acute self-poisoning with arsenic and treatment with BAL (author's transl)].
|
Wien Klin Wochenschr
|
1978
|
0.75
|
|
94
|
Plasmapheresis in the treatment of myasthenia gravis.
|
Wien Klin Wochenschr
|
1983
|
0.75
|
|
95
|
High dose single-agent paclitaxel in a hemodialysis patient with advanced ovarian cancer: a case report with pharmacokinetic analysis and review of the literature.
|
Int J Gynecol Cancer
|
2008
|
0.75
|
|
96
|
Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin.
|
Int J Oncol
|
1998
|
0.75
|
|
97
|
[Differential prognosis of patients with breast cancer with pleuritis carcinomatosa and with pulmonary lymphangiosis carcinomatosa].
|
Wien Klin Wochenschr
|
1992
|
0.75
|
|
98
|
[Quantitative determination of factor VIII antigen with an enzyme immunoassay].
|
Acta Biol Med Ger
|
1982
|
0.75
|
|
99
|
[Current status of interferon therapy].
|
Wien Med Wochenschr
|
1986
|
0.75
|
|
100
|
Effective salvage therapy with carboplatin/mitomycin C in metastatic breast cancer.
|
Onkologie
|
2002
|
0.75
|
|
101
|
[Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
|
Wien Klin Wochenschr
|
1993
|
0.75
|